Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection
David S. Fedson, Steven M. Opal, Ole Martin Rordam
Abstract
Patients with COVID-19 infection are at risk of acute respiratory disease syndrome (ARDS) and death. The tissue receptor for COVID-19 is ACE2, and higher levels of ACE2 can protect against ARDS. Angiotensin receptor blockers and statins upregulate ACE2. Clinical trials are needed to determine whether this drug combination might be used to treat patients with severe COVID-19 infection.
Topics & Concepts
ARDSCoronavirus disease 2019 (COVID-19)MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakDrugDiseaseIntensive care medicineImmunologyLungVirologyInternal medicineInfectious disease (medical specialty)PharmacologyOutbreakCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19SARS-CoV-2 and COVID-19 Research